Progressive supranuclear palsy

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy which can manifest clinically in a variety of syndromes. In this review, the classic and most common variant syndrome - PSP-Richardson's syndrome (PSP-RS) - is the focus, with the core clinical features, varying cognitive/motor/neuropsychiatric/sleep manifestations, neuropsychological findings, and typical neuroimaging findings all reviewed. Management strategies are also discussed. Of particular interest are the recently commenced clinical trials involving agents which affect key steps in the presumed pathogenesis of the tauopathies. The distinctive and recognizable characteristics of PSP-RS and advent of clinical trials involving potential disease modifying agents underscore the importance of identifying patients with this disorder and encouraging their involvement in trials.

Original languageEnglish (US)
JournalParkinsonism and Related Disorders
Volume18
Issue numberSUPPL. 1
StatePublished - Jan 2012

Fingerprint

Progressive Supranuclear Palsy
Tauopathies
Clinical Trials
Neuroimaging
Sleep

Keywords

  • Gait impairment
  • Gaze palsy
  • Parkinsonism
  • Tau

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Cite this

Progressive supranuclear palsy. / Boeve, Bradley F.

In: Parkinsonism and Related Disorders, Vol. 18, No. SUPPL. 1, 01.2012.

Research output: Contribution to journalArticle

@article{0a82229cc1764b52a6ecb9017a0d1c3e,
title = "Progressive supranuclear palsy",
abstract = "Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy which can manifest clinically in a variety of syndromes. In this review, the classic and most common variant syndrome - PSP-Richardson's syndrome (PSP-RS) - is the focus, with the core clinical features, varying cognitive/motor/neuropsychiatric/sleep manifestations, neuropsychological findings, and typical neuroimaging findings all reviewed. Management strategies are also discussed. Of particular interest are the recently commenced clinical trials involving agents which affect key steps in the presumed pathogenesis of the tauopathies. The distinctive and recognizable characteristics of PSP-RS and advent of clinical trials involving potential disease modifying agents underscore the importance of identifying patients with this disorder and encouraging their involvement in trials.",
keywords = "Gait impairment, Gaze palsy, Parkinsonism, Tau",
author = "Boeve, {Bradley F}",
year = "2012",
month = "1",
language = "English (US)",
volume = "18",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Progressive supranuclear palsy

AU - Boeve, Bradley F

PY - 2012/1

Y1 - 2012/1

N2 - Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy which can manifest clinically in a variety of syndromes. In this review, the classic and most common variant syndrome - PSP-Richardson's syndrome (PSP-RS) - is the focus, with the core clinical features, varying cognitive/motor/neuropsychiatric/sleep manifestations, neuropsychological findings, and typical neuroimaging findings all reviewed. Management strategies are also discussed. Of particular interest are the recently commenced clinical trials involving agents which affect key steps in the presumed pathogenesis of the tauopathies. The distinctive and recognizable characteristics of PSP-RS and advent of clinical trials involving potential disease modifying agents underscore the importance of identifying patients with this disorder and encouraging their involvement in trials.

AB - Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy which can manifest clinically in a variety of syndromes. In this review, the classic and most common variant syndrome - PSP-Richardson's syndrome (PSP-RS) - is the focus, with the core clinical features, varying cognitive/motor/neuropsychiatric/sleep manifestations, neuropsychological findings, and typical neuroimaging findings all reviewed. Management strategies are also discussed. Of particular interest are the recently commenced clinical trials involving agents which affect key steps in the presumed pathogenesis of the tauopathies. The distinctive and recognizable characteristics of PSP-RS and advent of clinical trials involving potential disease modifying agents underscore the importance of identifying patients with this disorder and encouraging their involvement in trials.

KW - Gait impairment

KW - Gaze palsy

KW - Parkinsonism

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=84858044950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858044950&partnerID=8YFLogxK

M3 - Article

VL - 18

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - SUPPL. 1

ER -